A H Ko

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 94115, USA
    Cancer Chemother Pharmacol 70:875-81. 2012
  2. ncbi Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
  3. ncbi A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Invest New Drugs 30:1597-606. 2012
  4. ncbi A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H Ko
    University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 66:1051-7. 2010
  5. ncbi A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA, 94115, USA
    Invest New Drugs 26:463-71. 2008
  6. ncbi Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA
    Cancer Invest 26:47-52. 2008
  7. ncbi Future strategies for targeted therapies and tailored patient management in pancreatic cancer
    Andrew H Ko
    Department of Medicine, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
    Semin Oncol 34:354-64. 2007
  8. ncbi A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer
    Andrew H Ko
    Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
    Int J Radiat Oncol Biol Phys 68:809-16. 2007
  9. ncbi Current and future strategies for combined-modality therapy in pancreatic cancer
    Andrew H Ko
    Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th Floor, San Francisco, CA 94115, USA
    Curr Oncol Rep 4:202-12. 2002
  10. ncbi Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 24:379-85. 2006

Detail Information

Publications19

  1. ncbi A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 94115, USA
    Cancer Chemother Pharmacol 70:875-81. 2012
    ....
  2. ncbi Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA
    Am J Clin Oncol 35:411-7. 2012
    ....
  3. ncbi A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma
    Andrew H Ko
    Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Invest New Drugs 30:1597-606. 2012
    ..To our knowledge, this is one of the first trials to evaluate a completely noncytotoxic regimen in the first-line treatment of advanced pancreatic cancer. (ClinicalTrials.gov number, NCT00326911)...
  4. ncbi A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
    Andrew H Ko
    University of California at San Francisco Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Cancer Chemother Pharmacol 66:1051-7. 2010
    ..Based on potential for additive or synergistic activity by concurrent inhibition of VEGF and EGFR, we conducted a phase II study evaluating the combination of bevacizumab plus erlotinib in this patient population...
  5. ncbi A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA, 94115, USA
    Invest New Drugs 26:463-71. 2008
    ..The objectives of this study were to determine safety and efficacy in chemotherapy-naive patients with metastatic pancreatic cancer receiving bevacizumab in combination with fixed-dose rate (FDR) gemcitabine and low-dose cisplatin...
  6. ncbi Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA
    Cancer Invest 26:47-52. 2008
    ..We, therefore, evaluated this regimen in patients with gemcitabine-refractory disease...
  7. ncbi Future strategies for targeted therapies and tailored patient management in pancreatic cancer
    Andrew H Ko
    Department of Medicine, University of California, San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
    Semin Oncol 34:354-64. 2007
    ..A newer strategy worth pursuing involves tailoring an individual patient's therapy according to the molecular characteristics of both host and tumor, as has shown promise in other solid tumor types...
  8. ncbi A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer
    Andrew H Ko
    Division of Hematology Oncology, University of California at San Francisco, San Francisco, CA 94115, USA
    Int J Radiat Oncol Biol Phys 68:809-16. 2007
    ..We conducted a Phase II nonrandomized trial to evaluate sequential chemotherapy followed by chemoradiation in this patient population...
  9. ncbi Current and future strategies for combined-modality therapy in pancreatic cancer
    Andrew H Ko
    Comprehensive Cancer Center, University of California at San Francisco, 1600 Divisadero Street, 4th Floor, San Francisco, CA 94115, USA
    Curr Oncol Rep 4:202-12. 2002
    ....
  10. ncbi Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas
    Andrew H Ko
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA 94115, USA
    J Clin Oncol 24:379-85. 2006
    ..The objectives of this study were to determine safety and efficacy in patients with metastatic pancreatic cancer treated with FDR gemcitabine in combination with low-dose cisplatin...
  11. ncbi Treatment of metastatic pancreatic cancer
    Andrew H Ko
    Division of Medical Oncology, University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94115, USA
    J Natl Compr Canc Netw 3:627-36. 2005
    ..This article provides the evidence to support each of these approaches and highlights future directions in the management of metastatic pancreatic cancer...
  12. ncbi Systemic therapy for pancreatic cancer
    Andrew H Ko
    San Francisco Comprehensive Cancer Center, University of California, San Francisco, CA, USA
    Semin Radiat Oncol 15:245-53. 2005
    ..The combination of standard cytotoxic agents and these newer targeted compounds offers promise that we will be able to make significant inroads in improving clinical outcomes for patients with advanced pancreatic cancer...
  13. ncbi Clinical outcomes associated with very late relapses in diffuse large cell lymphoma
    Andrew H Ko
    Division of Hematology Oncology, University of California, San Francisco Medical Center, San Francisco, CA 94115, USA
    Leuk Lymphoma 43:1789-93. 2002
    ..The overall poor prognosis in this group of patients justifies the use of more aggressive treatment approaches in the future, such as high dose therapy with stem cell support, rather than conventional salvage chemotherapy regimens...
  14. ncbi Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer
    A H Ko
    University of California at San Francisco Comprehensive Cancer Center, 1600 Divisadero Street, 4th Floor, Box 1705, San Francisco, CA 94115, USA
    Br J Cancer 93:195-9. 2005
    ....
  15. ncbi Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy
    Derrick Wong
    University of California at San Francisco Comprehensive Cancer Center, San Francisco, CA, USA
    Pancreas 37:269-74. 2008
    ..Serum carbohydrate antigen 19-9 (CA19-9) has never been compared to radiographic objective response as a surrogate for clinical outcomes in patients receiving chemotherapy for metastatic pancreatic cancer...
  16. ncbi A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies
    Amy J Chien
    Department of Medicine, University of California San Francisco, San Francisco, California 94143 0875, USA
    Clin Cancer Res 15:5569-75. 2009
    ..This study investigates the clinical relevance of this approach...
  17. ncbi Radiation therapy in operable and locally advanced pancreatic cancer
    Andrew H Ko
    Division of Hematology Oncology, University of California San Francisco Comprehensive Cancer Center, San Francisco, California, USA
    J Natl Compr Canc Netw 8:1022-31. 2010
    ....
  18. ncbi Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California
    Andrew H Ko
    Division of Hematology Oncology, University of California San Francisco, San Francisco, CA, USA
    Cancer Causes Control 18:809-19. 2007
    ..To determine the association between pancreatic cancer and medical conditions...
  19. ncbi Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature
    Andrew H Ko
    Division of Hematology and Oncology, University of California, San Francisco, California 94115, USA
    Dig Dis Sci 48:192-6. 2003